AmpliPhi Biosciences Corporation 3579 Valley Centre Drive, Suite 100 San Diego, CA 92130 Press Release AmpliPhi Biosciences Reports First Quarter 2016 Financial Results and Provides Corporate Update San Diego

AmpliPhi Biosciences Reports First Quarter

2016 Financial Results and

Provides Corporate Update

May 12, 2016 - AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based

antibacterial therapies to treat drug-resistant infections, today announced its financial results for the first quarter ended March

"We have made significant progress in 2016, effectively

executing on our clinical development and business strategies," said M. Scott Salka, CEO of AmpliPhi Biosciences. "We

acquired additional bacteriophage assets, presented in vitro data for AB-PA01 for Pseudomonas aeruginosa, dosed our

first patient and successfully completed the first cohort in our Phase I clinical trial of AB-SA01 for the treatment of Staphylococcus

aureus infections in patients with chronic rhinosinusitis. We also saw our outstanding Series B Preferred stock be converted

to Common, thereby streamlining our capital structure."

Highlights Demonstrate Progress in R&D, Governance, and

First Quarter 2016 Financial Results:

For more information, visit www.ampliphibio.com.

Conference Call Details

AmpliPhi Biosciences will host a conference call and webcast

to discuss its first quarter 2016 financial results and provide an update on business activities. The event will be held tomorrow,

May 13, 2016, at 8:30 a.m. Eastern Time (ET). The live event can be accessed through AmpliPhi's website at www.ampliphibio.com

under the Events and Presentations section, or by calling 844-745-6357 (US) or 661-378-9813 (outside of the US). The

passcode is 10677209. A replay of the discussion will be available beginning at approximately 11:30 a.m. ET tomorrow on AmpliPhi's

website or by calling 855-859-2056 (US) or 404-537-3406 (outside of the US), using conference ID 10677209.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation (NYSE MKT: APHB) is a biotechnology

company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi's product

development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is currently conducting

a Phase I clinical trial of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients and expects

to report final data in the second half of 2016. AmpliPhi is also developing bacteriophage therapeutics targeting Pseudomonas

aeruginosa and Clostridium difficile in collaboration with a number of leading organizations focused on the advancement

of bacteriophage-based therapies.

Bacteriophage are naturally occurring viruses that are highly

specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage

are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for

bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels,

to produce strong local therapeutic effects.

Forward Looking Statements

Statements in this press release that are not statements of

historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such

forward-looking statements include, without limitation, statements about the value of AmpliPhi's bacteriophage assets, AmpliPhi's

ability to form collaborations and access technologies, the timing of reporting of data from clinical trials, the sufficiency of

cash to fund future operations, the anticipated advancement of AmpliPhi's pre-clinical and clinical

pipelines in 2016, the potential use of bacteriophages to treat bacterial infections, including infections that do not respond

to antibiotics, and AmpliPhi's development of bacteriophage-based therapies. Words such as "believe," "anticipate,"

"plan," "expect," "intend," "will," "may," "goal," "potential"

and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily

contain these identifying words. These forward-looking statements are based upon AmpliPhi's current expectations and involve

a number of risks and uncertainties, including the risks and uncertainties described in AmpliPhi's Annual Report on Form

10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission (SEC) on March 30, 2016, and Form 10-Q

for the quarter ended March 31, 2016 to be filed with the Securities and Exchange Commission on or about May 12, 2016. Actual results

and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these

risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as

of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement,

and AmpliPhi undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after

the date of this press release.